Awaiting development: Guidance and quality standards

Showing 31 to 40 of 303

Guidance and quality standards awaiting development
Title	Type
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]	Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]	Technology appraisal guidance
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]	Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344]	Technology appraisal guidance
Bepirovirsen for treating chronic hepatitis B [ID6608]	Technology appraisal guidance
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]	Technology appraisal guidance
Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]	Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]	Technology appraisal guidance
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]	Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis [TSID10334]	Technology appraisal guidance